Nothing Special   »   [go: up one dir, main page]

MX2020011588A - Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. - Google Patents

Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.

Info

Publication number
MX2020011588A
MX2020011588A MX2020011588A MX2020011588A MX2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A MX 2020011588 A MX2020011588 A MX 2020011588A
Authority
MX
Mexico
Prior art keywords
lag
binding proteins
high affinity
affinity antibodies
made therefrom
Prior art date
Application number
MX2020011588A
Other languages
English (en)
Inventor
Xuan Wu
Shiyong Gong
Chengbin Wu
Original Assignee
Shanghai Epimab Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Epimab Biotherapeutics Co Ltd filed Critical Shanghai Epimab Biotherapeutics Co Ltd
Publication of MX2020011588A publication Critical patent/MX2020011588A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos de alta afinidad que reconocen el Ligando 1 de Muerte Programada (PD-1) y la proteína del Gen 3 de Activación Linfocitica (LAG-3). Los sitios de unión de los anticuerpos anti-PD-1 y anti-LAG-3 humanizados se incorporan en un formato de inmunoglobulina Fabs-en-Tandem sin pérdida significativa de afinidad de unión, y las proteínas de unión biespecíficas y multivalentes resultantes pueden unirse tanto a PD- 1 y LAG-3 simultáneamente. Tales proteínas de unión a FIT-Ig biespecíficas son útiles para el tratamiento del cáncer.
MX2020011588A 2018-05-03 2019-04-30 Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. MX2020011588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018085468 2018-05-03
PCT/CN2019/085164 WO2019210848A1 (en) 2018-05-03 2019-04-30 High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Publications (1)

Publication Number Publication Date
MX2020011588A true MX2020011588A (es) 2020-12-07

Family

ID=68386276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011588A MX2020011588A (es) 2018-05-03 2019-04-30 Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.

Country Status (11)

Country Link
US (1) US12060425B2 (es)
EP (1) EP3788079A4 (es)
JP (1) JP7368453B2 (es)
KR (1) KR20210005894A (es)
CN (1) CN112074541A (es)
AU (1) AU2019263850A1 (es)
BR (1) BR112020022371A2 (es)
CA (1) CA3097916A1 (es)
MX (1) MX2020011588A (es)
TW (1) TWI784190B (es)
WO (1) WO2019210848A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769133C2 (ru) * 2013-12-30 2022-03-28 Эпимаб Биотерапьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
MX2022006230A (es) * 2019-11-26 2022-06-22 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
CN115819585B (zh) * 2020-12-10 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
WO2022166987A1 (zh) * 2021-02-08 2022-08-11 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
TW202300516A (zh) * 2021-03-10 2023-01-01 大陸商北京拓界生物醫藥科技有限公司 Pd—1結合蛋白及其醫藥用途
CR20230462A (es) * 2021-03-31 2023-11-30 Incyte Corp Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 novedosos.
CN114989297B (zh) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 包含辣根过氧化物酶标记的抗体的试剂盒
TW202421193A (zh) * 2022-09-28 2024-06-01 美商英塞特公司 抗pd-1/lag-3雙特異性抗體及其用途

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1297172B1 (en) 2000-06-28 2005-11-09 Glycofi, Inc. Methods for producing modified glycoproteins
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン,インコーポレーテッド 抗体のヒト化
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20050250185A1 (en) 2003-12-12 2005-11-10 Murphy Andrew J OGH fusion polypeptides and therapeutic uses thereof
PL1730191T3 (pl) 2004-03-30 2011-12-30 Glaxo Group Ltd Immunoglobuliny wiążące hosm
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP1863844A1 (en) 2005-02-28 2007-12-12 Centocor, Inc. Heterodimeric protein binding compositions
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP2484774A3 (en) 2005-07-21 2012-11-14 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
DK2481753T3 (en) 2005-12-13 2018-06-18 Lilly Co Eli Anti-IL-17 antibodies
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
CA2716851A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー/エス 抗ヒトインターロイキン−20抗体
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8802375B2 (en) 2009-09-14 2014-08-12 Icahn School Of Medicine At Mount Sinai Methods for characterizing antibody binding affinity and epitope diversity in food allergy
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US9862769B2 (en) 2010-05-27 2018-01-09 Genmab A/S Monoclonal antibodies against HER2
WO2012025525A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
SG10201604699VA (en) 2010-12-21 2016-07-28 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ, インク. 二重特異性三鎖抗体様分子
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
LT2748202T (lt) 2011-08-23 2018-09-25 Roche Glycart Ag Bispecifinės antigeną surišančios molekulės
JP6339015B2 (ja) 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー 二重特異性t細胞活性化抗原結合分子
NO2802607T3 (es) 2012-01-13 2018-03-03
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ヒトtweak及びヒトil17に対する二重特異性抗体並びにその使用
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
US20160009824A1 (en) 2013-03-15 2016-01-14 Merck Patent Gmbh Tetravalent bispecific antibodies
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014166029A1 (zh) 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
BR112016011222A2 (pt) 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
RU2769133C2 (ru) * 2013-12-30 2022-03-28 Эпимаб Биотерапьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015134411A1 (en) 2014-03-03 2015-09-11 Academia Sinica Bi-specific antibodies and uses thereof
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
EP3760229A3 (en) 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
PL3608337T3 (pl) 2014-08-04 2024-07-22 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujący limfocyty T
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AR101875A1 (es) 2014-09-15 2017-01-18 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
PT3212226T (pt) 2014-10-31 2020-06-22 Ngm Biopharmaceuticals Inc Composições e métodos de utilização para tratamento de distúrbios metabólicos
EP3215538A4 (en) 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
EP3747905A1 (en) 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20181151A1 (es) * 2015-07-30 2018-07-17 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
WO2017087589A2 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
JP2019509014A (ja) 2015-11-23 2019-04-04 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Cd39血管アイソフォームターゲティング剤
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
MX2018009581A (es) 2016-02-06 2019-05-06 Epimab Biotherapeutics Inc Inmunoglobulina con fabs en tandem y sus usos.
TW202408578A (zh) * 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
SG11201811064TA (en) 2016-06-20 2019-01-30 F Star Delta Ltd Binding molecules binding pd-l1 and lag-3
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业(苏州)有限公司 一种新的pd-1单克隆抗体
KR20230136711A (ko) 2016-10-13 2023-09-26 치아타이 티안큉 파마수티컬 그룹 주식회사 항-lag-3 항체 및 조성물
EP3565833A1 (en) 2017-01-09 2019-11-13 Torch Therapeutics Conditionally effective bispecific therapeutics
US11345757B2 (en) 2017-07-31 2022-05-31 Trishula Therapeutics, Inc. Anti-CD39 antibodies
AU2018346447A1 (en) 2017-10-06 2020-03-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
BR112020009655A8 (pt) 2017-11-15 2023-03-21 Innate Pharma Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
CA3150168A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats

Also Published As

Publication number Publication date
US20210188980A1 (en) 2021-06-24
EP3788079A1 (en) 2021-03-10
CN112074541A (zh) 2020-12-11
WO2019210848A1 (en) 2019-11-07
EP3788079A4 (en) 2022-12-21
TWI784190B (zh) 2022-11-21
TW202041537A (zh) 2020-11-16
JP7368453B2 (ja) 2023-10-24
KR20210005894A (ko) 2021-01-15
CA3097916A1 (en) 2019-11-07
AU2019263850A1 (en) 2020-11-19
BR112020022371A2 (pt) 2021-02-02
JP2021522347A (ja) 2021-08-30
US12060425B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2022006230A (es) Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
AU2018334886A1 (en) Novel bispecific polypeptide complexes
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
WO2016126858A3 (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
MX2019010392A (es) Moleculas de fusion de ectodominios receptores de tgf-b y sus usos.
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
WO2020123662A3 (en) Fusion protein constructs for complement associated disease
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.